lifestyle.thedishh.com

Author: UroGen Pharma Ltd.

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

May 13, 2026
UroGen Pharma to Present at Upcoming Investor Conferences

May 7, 2026
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

May 7, 2026
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

May 5, 2026
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

May 2, 2026
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence

April 29, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

March 30, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 6, 2026
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

March 2, 2026
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

March 2, 2026